R. Henderson

发表

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.

M. Drayson, M. Jenner, G. Cook, 2022, BMJ open.

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

M. Drayson, M. Jenner, G. Cook, 2021, BMJ Open.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

G. L. Masson, D. Yarnitsky, S. Muley, 2018, The Lancet Neurology.

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.

S. Naicker, M. Cahill, J. Krawczyk, 2021, Clinical lymphoma, myeloma & leukemia.

Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV

M. Drayson, M. Jenner, G. Cook, 2019, Blood.

OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk

G. Morgan, W. Gregory, M. Drayson, 2021, Clinical Lymphoma Myeloma and Leukemia.

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

S. Groshen, A. Gabizon, F. Muggia, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

G. Morgan, W. Gregory, M. Drayson, 2016, Blood Cancer Journal.

Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2

S. Jeffers, S. Groshen, A. Gabizon, 2005 .

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

G. Morgan, W. Gregory, M. Drayson, 2017 .

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

G. Morgan, W. Gregory, M. Drayson, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

M. Drayson, M. Jenner, F. Davies, 2022, Blood.

Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials

M. Drayson, M. Jenner, G. Cook, 2021, Blood.